Although PARP inhibitors considerably improved the therapeutic response of BRCA-mutant BC, inter- and intra-tumor heterogeneity limits the treatment efficacy and causes the selection and expansion of the aggressive CSC pool expressing Rad51, responsible for DNA-damage repair via HR [18, 19]. Here, PARP1 is linked to breast cancer.